News
SABSW
0.0304
0.00%
0.0000
Weekly Report: what happened at SABSW last week (0415-0419)?
Weekly Report · 3d ago
SAB BIOTHERAPEUTICS: COMPLETED DOSING THIRD COHORT FOR SAB-142 WITH NO OBSERVATION OF SERUM SICKNESS THUS FAR
Reuters · 04/16 11:15
SAB Biotherapeutics Provides SAB-142 Trial Update
SAB has completed dosing the third cohort for SAB-142 with no observation of serum sickness. SAB is developing human anti-thymocyte immunoglobulin for delaying onset or progression of type 1 diabetes (T1D) SAB Biotherapeutics, Inc. Is a clinical-stage biopharmaceutical company.
Barchart · 04/16 06:15
SAB BIOTHERAPEUTICS: ON APRIL 12, COMPLETED DOSING OF COHORT 3 FOR PHASE ONE TRIALS OF SAB-142, HAS NOT OBSERVED ANY INSTANCES OF SERUM SICKNESSES
Reuters · 04/15 21:16
Weekly Report: what happened at SABSW last week (0408-0412)?
Weekly Report · 04/15 11:30
Weekly Report: what happened at SABSW last week (0401-0405)?
Weekly Report · 04/08 11:34
SAB Biotherapeutics to Present at INNODIA Annual Meeting
SAB Biotherapeutics will be featured as a key partner at the INNODIA Annual Meeting in Leuven, Belgium on April 11, 2024. SAB is developing a novel immunotherapy platform for delaying the onset or progression of type 1 diabetes. Chief Medical Officer will share an overview of the SAB-142 clinical development plan.
Barchart · 04/08 06:15
SAB Biotherapeutics to Present at the Needham Virtual Healthcare Conference
SAB Biotherapeutics, Inc. Will present an overview of the company at the 23rd Annual Needham Virtual Conference on April 11, 2024. The company is developing a novel immunotherapy platform for delaying the onset or progression of type 1 diabetes. Samuel J. Reich, the company's Chairman and CEO, will present.
Barchart · 04/04 06:15
SAB Biotherapeutics Inc reports results for the quarter ended in December - Earnings Summary
SAB Biotherapeutics Inc reports results for the quarter ended in December. The company reported a quarterly adjusted loss of $3.38 per share. Revenue was $305.00 thousand; analysts expected zero. SAB shares have fallen by 5.5% this quarter and 37.6% this year.
Reuters · 04/02 22:47
SAB BIOTHERAPEUTICS INC <SABS.O>: CHARDAN CAPITAL MARKETS ADJUSTS TARGET PRICE TO $25 FROM $3 TO REFLECT 1-FOR-10 REVERSE STOCK SPLIT
Reuters · 04/02 11:48
Weekly Report: what happened at SABSW last week (0325-0329)?
Weekly Report · 04/01 11:31
SAB Biotherapeutics Reports Full Year 2023 Operating and Financial Results
Barchart · 03/29 06:15
SAB Biotherapeutics Inc <SABS.OQ> expected to post a loss of 62 cents a share - Earnings Preview
SAB Biotherapeutics Inc expected to post a loss of 62 cents a share - Earnings Preview. The company is expected to report results on March 29 for the period ending December 31 2023. The average analyst estimate for the company is for a Loss of 62 cents per share.
Reuters · 03/27 11:18
Weekly Report: what happened at SABSW last week (0318-0322)?
Weekly Report · 03/25 11:35
Weekly Report: what happened at SABSW last week (0311-0315)?
Weekly Report · 03/18 11:33
Weekly Report: what happened at SABSW last week (0304-0308)?
Weekly Report · 03/11 11:29
Weekly Report: what happened at SABSW last week (0226-0301)?
Weekly Report · 03/04 11:32
Weekly Report: what happened at SABSW last week (0219-0223)?
Weekly Report · 02/26 11:47
SAB BIOTHERAPEUTICS INC: Statement of changes in beneficial ownership of securities
Press release · 02/24 08:15
SAB Biotherapeutics to Present at the BIO CEO & Investor Conference
SAB Biotherapeutics, Inc. Is developing a novel immunotherapy platform for delaying the onset or progression of type 1 diabetes. Samuel J. Reich, the Company’s Chairman and CEO, will present an overview of the Company at the BIO CEO & Investor Conference on February 26, 2024.
Barchart · 02/23 07:00
More
Webull provides a variety of real-time SABSW stock news. You can receive the latest news about SAB BIOTHERAPEUTICS INC through multiple platforms. This information may help you make smarter investment decisions.
About SABSW
SAB Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing fully human, multi- targeted, high-potency immunoglobulins (IgGs), without the need for human donors or convalescent plasma, to treat and prevent immune and autoimmune disorders. The Company's lead asset, SAB-142, targets type 1 diabetes (T1D) with a disease-modifying therapeutic approach. Using advanced genetic engineering and antibody science to develop Transchromosomic (Tc) Bovine, the only transgenic animal with a human artificial chromosome, its DiversitAb drug development production system is able to generate a diverse repertoire of specifically targeted, high-potency, fully-human IgGs that can address a wide range of serious unmet needs in human diseases. The Company's SAB-176 pipeline program is a multivalent, broadly neutralizing -human polyclonal IgG therapeutic candidate in development for the treatment or prevention of severe influenza.